Literature DB >> 20418024

Radiotherapy for patients with metastases to the spinal column: a review of 603 patients at Shizuoka Cancer Center Hospital.

Masashi Mizumoto1, Hideyuki Harada, Hirofumi Asakura, Takayuki Hashimoto, Kazuhisa Furutani, Haruko Hashii, Hideki Murata, Tatsuya Takagi, Hirohisa Katagiri, Mitsuru Takahashi, Tetsuo Nishimura.   

Abstract

PURPOSE: Long- and short-course radiotherapy have similar outcomes in the treatment of spinal metastases. Long-course radiotherapy is recommended for patients with good predicted survival to reduce the risk of in-field recurrence, whereas short-course radiotherapy is used for those with poor predicted survival. Therefore, prediction of prognosis and local control is required for selecting the optimal course of radiotherapy. METHODS AND MATERIALS: The subjects were 603 patients with spinal metastases who received radiotherapy at the Shizuoka Cancer Center Hospital between September 2002 and February 2007. Factors associated with survival and local control were retrospectively investigated by multivariate analyses. Local recurrence was defined as regrowth within the irradiated field or exacerbation of symptoms such as pain and motor deficits.
RESULTS: Of the 603 patients, 555 (92%) were followed for 12 months or until death. The survival rates after 6, 12, and 24 months were 50%, 32%, and 19%, respectively, with a median survival of 6.2 months. The median survival periods after long- and short-course radiotherapy were 7.9 and 1.8 months, respectively. In multivariate analysis, primary tumor site, good performance status, absence of previous chemotherapy, absence of visceral metastasis, single bone metastasis, younger age, and nonhypercalcemia were associated with good survival. The local control rates after 6, 12, and 24 months were 91%, 79%, and 69%, respectively, and non-mass-type tumor, breast cancer, and absence of previous chemotherapy were predictors of good local control.
CONCLUSIONS: Identification of factors associated with good local control and survival may allow selection of an optimal radiotherapy schedule for patients with spinal metastases.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20418024     DOI: 10.1016/j.ijrobp.2009.10.056

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  30 in total

1.  Effective local control of vertebral metastases by simultaneous integrated boost radiotherapy: preliminary results.

Authors:  Dorota Lubgan; Anke Ziegaus; Sabine Semrau; Ulrike Lambrecht; Sebastian Lettmaier; Rainer Fietkau
Journal:  Strahlenther Onkol       Date:  2014-11-14       Impact factor: 3.621

2.  Radiotherapy combined with zoledronate can reduce skeletal-related events in renal cell carcinoma patients with bone metastasis.

Authors:  Seiichi Hosaka; Hirohisa Katagiri; Masashi Niwakawa; Hideyuki Harada; Junji Wasa; Hideki Murata; Mitsuru Takahashi
Journal:  Int J Clin Oncol       Date:  2018-06-29       Impact factor: 3.402

3.  The impact of histology and delivered dose on local control of spinal metastases treated with stereotactic radiosurgery.

Authors:  Yoshiya Yamada; Evangelia Katsoulakis; Ilya Laufer; Michael Lovelock; Ori Barzilai; Lily A McLaughlin; Zhigang Zhang; Adam M Schmitt; Daniel S Higginson; Eric Lis; Michael J Zelefsky; James Mechalakos; Mark H Bilsky
Journal:  Neurosurg Focus       Date:  2017-01       Impact factor: 4.047

4.  Clinical outcomes of multileaf collimator-based CyberKnife for spine stereotactic body radiation therapy.

Authors:  Nalee Kim; Ho Lee; Jin Sung Kim; Jong Geal Baek; Chang Geol Lee; Sei Kyung Chang; Woong Sub Koom
Journal:  Br J Radiol       Date:  2017-09-04       Impact factor: 3.039

5.  A systematic review of prognostic factors predicting survival in patients with spinal bone metastases.

Authors:  L Bollen; W C H Jacobs; Y M Van der Linden; O Van der Hel; W Taal; P D S Dijkstra
Journal:  Eur Spine J       Date:  2017-10-24       Impact factor: 3.134

6.  The era of stereotactic body radiotherapy for spinal metastases and the multidisciplinary management of complex cases.

Authors:  Rachit Kumar; Anick Nater; Ahmed Hashmi; Sten Myrehaug; Young Lee; Lijun Ma; Kristin Redmond; Simon S Lo; Eric L Chang; Albert Yee; Charles G Fisher; Michael G Fehlings; Arjun Sahgal
Journal:  Neurooncol Pract       Date:  2015-07-27

7.  Single-fraction radiotherapy versus multifraction radiotherapy for palliation of painful vertebral bone metastases-equivalent efficacy, less toxicity, more convenient: a subset analysis of Radiation Therapy Oncology Group trial 97-14.

Authors:  David D Howell; Jennifer L James; William F Hartsell; Mohan Suntharalingam; Mitchell Machtay; John H Suh; William F Demas; Howard M Sandler; Lisa A Kachnic; Lawrence B Berk
Journal:  Cancer       Date:  2012-11-16       Impact factor: 6.860

Review 8.  The importance of multidisciplinary care for spine metastases: initial tumor management.

Authors:  William Christopher Newman; Ankur Patel; Jacob L Goldberg; Mark H Bilsky
Journal:  Neurooncol Pract       Date:  2020-11-18

Review 9.  Update on management of vertebral column tumors.

Authors:  James K C Liu; Ilya Laufer; Mark H Bilsky
Journal:  CNS Oncol       Date:  2014-03

Review 10.  Stereotactic body radiotherapy: a new paradigm in the management of spinal metastases.

Authors:  Zain A Husain; Isabelle Thibault; Daniel Letourneau; Lijun Ma; Harald Keller; John Suh; Veronica Chiang; Eric L Chang; Raja K Rampersaud; James Perry; David A Larson; Arjun Sahgal
Journal:  CNS Oncol       Date:  2013-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.